https://charts.traderzeitung.de/phases/GB00BRXB0C07
string(1439) "{"isin":"GB00BRXB0C07","name":"Kiniksa Pharmaceuticals International PLC","stock_id_xnas":65845193,"stock_id_xnys":null,"generated_at":"2026-09-24 01:36:00","days":[{"date":"2026-09-21","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":78.17,"close_at":"2026-09-21 21:59:00","complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-22","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":78.65,"close_at":"2026-09-22 10:03:00","complete":true,"perf_pct":0.614},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":78.02,"close_at":"2026-09-22 21:59:00","complete":true,"perf_pct":-0.801},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-23","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":76.02,"close_at":"2026-09-23 21:59:00","complete":true,"perf_pct":-2.5634},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":false,"perf_pct":null}]}]}"
Kiniksa Pharmaceuticals International Aktie News & Nachrichten
Trading-Room

Kiniksa Pharmaceuticals International Aktie News & Nachrichten

[WKN: A40H21 | Symbol: KNSA]
Realtimekurs
   
Kiniksa Pharmaceuticals International Plc is a commercial-stage biopharmaceutical company. It engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. The company was founded on April 9, 2024 and is headquartered in London, United Kingdom.
Vorbörsliche Indikationen
Regulärer Handel
Nachbörslicher Handel

Artikel aus der Redaktion der Trader-Zeitung

Kiniksa Pharmaceuticals International

TOP-5-Kursziele der Analysten am 29.09.25

Innoviz Technologies [IL0011745804] Goldman Sachs nimmt Hochstufung von "Neutral" auf "Buy" vor und...

  • ‹
  • 1
  • ›
Kiniksa Pharmaceuticals International Nachrichtenticker öffnen
MT Newswires 28.07.2026 20:27 Uhr

Größte Gewinner zur Mittagszeit

14:26 Uhr EDT, 28.07.2026 (MT Newswires) -- Kiniksa Pharmaceuticals International (KNSA) meldete am Dienstag einen Nettogewinn und Umsatz im zweiten Q

MT Newswires 28.07.2026 17:41 Uhr

Kiniksas Wachstumsaussichten für Arcalyst verbessern sich, sagt Wedbush

11:40 AM EDT, 28.07.2026 (MT Newswires) -- Kiniksa Pharmaceuticals International (KNSA) profitiert von einer anhaltenden Dynamik bei Arcalyst, der Beh

MT Newswires 28.07.2026 16:42 Uhr

Wedbush erhöht das Kursziel für Kiniksa Pharmaceuticals von 72 USD auf 99 USD und belässt die Einstufung auf Outperform

10:41 AM EDT, 28.07.2026 (MT Newswires) -- Kiniksa Pharmaceuticals International (KNSA) hat laut von FactSet befragten Analysten ein durchschnittliche

MT Newswires 28.07.2026 13:51 Uhr

Kiniksa Pharmaceuticals International: Nettogewinn und Umsatz steigen im zweiten Quartal

07:50 AM EDT, 28.07.2026 (MT Newswires) -- Kiniksa Pharmaceuticals International (KNSA) meldete am Dienstag einen Nettogewinn im zweiten Quartal von 0

MT Newswires 28.07.2026 13:36 Uhr

--Earnings Flash (KNSA) Kiniksa Pharmaceuticals meldet Q2 EPS von 0,30 USD, verglichen mit der FactSet-Schätzung von 0,28 USD

07:35 AM EDT, 28.07.2026 (MT Newswires) -- http://www.mtnewswires.com Copyright © 2026 MT Newswires. All rights reserved. MT Newswires does not provid

MT Newswires 28.07.2026 13:31 Uhr

Earnings Flash (KNSA) Kiniksa Pharmaceuticals International, plc meldet Q2 Umsatz von 243,6 Mio. $, ggü. FactSet-Schätzung von 226,5 Mio. $

07:30 AM EDT, 28.07.2026 (MT Newswires) -- http://www.mtnewswires.com Copyright © 2026 MT Newswires. All rights reserved. MT Newswires does not provid

MT Newswires 28.07.2026 13:31 Uhr

-- Earnings Flash (KNSA) Kiniksa Pharmaceuticals International, plc meldet Q2-Umsatz von 243,6 Mio. $, gegenüber FactSet-Schätzung von 226,5 Mio. $

07:30 AM EDT, 28.07.2026 (MT Newswires) -- http://www.mtnewswires.com Copyright © 2026 MT Newswires. All rights reserved. MT Newswires does not provid

MT Newswires 29.06.2026 13:10 Uhr

Wedbush erhöht das Kursziel für Kiniksa Pharmaceuticals International auf $72 von $59, behält das 'Outperform'-Rating bei

07:09 AM EDT, 06/29/2026 (MT Newswires) -- Kiniksa Pharmaceuticals International (KNSA) hat ein durchschnittliches 'Buy'-Rating und ein mittleres Kurs